国家卫健委:做好中选药品临床使用情况监测工作

2019-01-27 红头文件 国家卫生健康委员会官网

国务院办公厅印发了《国家组织药品集中采购和使用试点方案》,对此,国家卫健委提出五点要求

国家卫生健康委办公厅关于做好国家组织药品集中采购中选药品临床配备使用工作的通知

国卫办医函〔2019〕77号

北京市、天津市、辽宁省、上海市、福建省、广东省、重庆市、四川省、陕西省卫生健康委:

近期,国务院办公厅印发了《国家组织药品集中采购和使用试点方案》,决定在北京、天津、上海、重庆和沈阳、大连、厦门、广州、深圳、成都、西安11个城市开展国家组织药品集中采购和使用试点,阿托伐他汀钙片等药品中选。为贯彻落实党中央、国务院决策部署和试点工作要求,做好中选药品的配备使用,切实降低群众药费负担,现将有关要求通知如下:

一、高度重视中选药品配备使用工作

党中央、国务院高度重视人民健康福祉。国家组织药品集中采购和使用试点是落实国务院“确保群众用上质优价廉的药品”要求的重要举措,是对既往药品集中采购制度的重大改革,也是我国医改深化发展的具体体现。试点地区的卫生健康行政部门要牢固树立“四个意识”,高度重视中选药品的临床配备使用工作,加强指导和调度,稳妥推进试点。公立医疗机构要落实国务院办公厅方案要求,配备和合理使用中选药品,切实保证用量,进一步降低群众药费负担。

二、畅通优先使用中选药品的政策通道

各级卫生健康行政部门要加强对公立医疗机构使用中选药品的指导和监督,要按照约定的采购量督促公立医疗机构优先采购和使用中选药品,确保1年内完成合同用量。卫生健康行政部门和医疗机构不得以费用控制、药占比和医疗机构用药品种规格数量要求等为由,影响中选药品的合理使用与供应保障。公立医疗机构要优化用药结构,将中选药品纳入医疗机构的药品处方集和基本用药供应目录,严格落实按药品通用名开具处方的要求,确保在同等条件下优先选择使用中选药品。

三、提高中选药品的合理使用水平

医疗机构要及时制定完善中选药品的临床用药指南,规范医师用药行为。大力开展医师宣传培训,使其了解国家组织药品集中采购和使用试点的政策意义,掌握药品合理使用的基本原则和注意事项,提高合理使用水平。严格落实《处方管理办法》《医疗机构药事管理规定》《医院处方点评管理规范(试行)》及相关诊疗规范、用药指南,加强处方审核和处方点评,并充分发挥临床药师作用,保障患者用药安全。对使用中选药品可能导致患者用药调整的情况,各医疗机构要做好临床风险评估、预案制定和物资储备,做好用药情况监测及应急处置,并对患者做好解释说明。

四、建立完善相关激励机制和绩效考核制度

卫生健康行政部门要将公立医疗机构执行带量采购情况纳入医疗机构绩效考核,并要求医疗机构将其纳入临床科室和医师绩效考核,建立鼓励使用中选药品的激励机制和倾斜措施。要通过阳光采购平台、官方网站等定期公示医疗机构采购、使用中选药品的比例和排名,接受社会监督。对于优先使用、保证用量的医疗机构、临床科室和医师,要在公立医院改革奖补资金、评优评先、职称评定中予以倾斜;对于不能及时按要求配备或采购量不足,影响患者用药需求的,要在医疗机构等级评审、医疗机构负责人目标责任考核中作出相应处理,对医疗机构采取通报批评、限期整改、考核和评价不合格等措施。

五、做好中选药品临床使用情况监测

省级卫生健康行政部门要建立完善药品临床使用监测网络,将试点城市的所有公立医疗机构纳入监测范围。充分利用信息化手段,对中选药品配备采购和使用情况、临床效果等进行监测和分析,掌握试点地区工作进展。对可能存在问题的地区提前预警,必要时开展现场督查,确保试点工作顺利实施。

试点过程中遇到问题请及时与我委联系。我委将适时组织督导检查,对工作落实不力的省份和医疗机构,予以全国通报和约谈。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1660832, encodeId=ac56166083259, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Wed Jun 19 22:52:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689929, encodeId=da4f1689929d9, content=<a href='/topic/show?id=c5f2226e9d3' target=_blank style='color:#2F92EE;'>#临床使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22679, encryptionId=c5f2226e9d3, topicName=临床使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=703d28925250, createdName=12498e87m48暂无昵称, createdTime=Wed Jun 26 08:52:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258540, encodeId=09521258540d0, content=<a href='/topic/show?id=b0ae365e02f' target=_blank style='color:#2F92EE;'>#卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36570, encryptionId=b0ae365e02f, topicName=卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Tue Jan 29 02:52:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291159, encodeId=755712911591b, content=<a href='/topic/show?id=e53140859f6' target=_blank style='color:#2F92EE;'>#国家卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40859, encryptionId=e53140859f6, topicName=国家卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Tue Jan 29 02:52:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359374, encodeId=a7f33593e439, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jan 27 14:11:01 CST 2019, time=2019-01-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1660832, encodeId=ac56166083259, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Wed Jun 19 22:52:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689929, encodeId=da4f1689929d9, content=<a href='/topic/show?id=c5f2226e9d3' target=_blank style='color:#2F92EE;'>#临床使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22679, encryptionId=c5f2226e9d3, topicName=临床使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=703d28925250, createdName=12498e87m48暂无昵称, createdTime=Wed Jun 26 08:52:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258540, encodeId=09521258540d0, content=<a href='/topic/show?id=b0ae365e02f' target=_blank style='color:#2F92EE;'>#卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36570, encryptionId=b0ae365e02f, topicName=卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Tue Jan 29 02:52:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291159, encodeId=755712911591b, content=<a href='/topic/show?id=e53140859f6' target=_blank style='color:#2F92EE;'>#国家卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40859, encryptionId=e53140859f6, topicName=国家卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Tue Jan 29 02:52:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359374, encodeId=a7f33593e439, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jan 27 14:11:01 CST 2019, time=2019-01-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1660832, encodeId=ac56166083259, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Wed Jun 19 22:52:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689929, encodeId=da4f1689929d9, content=<a href='/topic/show?id=c5f2226e9d3' target=_blank style='color:#2F92EE;'>#临床使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22679, encryptionId=c5f2226e9d3, topicName=临床使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=703d28925250, createdName=12498e87m48暂无昵称, createdTime=Wed Jun 26 08:52:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258540, encodeId=09521258540d0, content=<a href='/topic/show?id=b0ae365e02f' target=_blank style='color:#2F92EE;'>#卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36570, encryptionId=b0ae365e02f, topicName=卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Tue Jan 29 02:52:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291159, encodeId=755712911591b, content=<a href='/topic/show?id=e53140859f6' target=_blank style='color:#2F92EE;'>#国家卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40859, encryptionId=e53140859f6, topicName=国家卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Tue Jan 29 02:52:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359374, encodeId=a7f33593e439, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jan 27 14:11:01 CST 2019, time=2019-01-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1660832, encodeId=ac56166083259, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Wed Jun 19 22:52:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689929, encodeId=da4f1689929d9, content=<a href='/topic/show?id=c5f2226e9d3' target=_blank style='color:#2F92EE;'>#临床使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22679, encryptionId=c5f2226e9d3, topicName=临床使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=703d28925250, createdName=12498e87m48暂无昵称, createdTime=Wed Jun 26 08:52:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258540, encodeId=09521258540d0, content=<a href='/topic/show?id=b0ae365e02f' target=_blank style='color:#2F92EE;'>#卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36570, encryptionId=b0ae365e02f, topicName=卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Tue Jan 29 02:52:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291159, encodeId=755712911591b, content=<a href='/topic/show?id=e53140859f6' target=_blank style='color:#2F92EE;'>#国家卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40859, encryptionId=e53140859f6, topicName=国家卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Tue Jan 29 02:52:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359374, encodeId=a7f33593e439, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jan 27 14:11:01 CST 2019, time=2019-01-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1660832, encodeId=ac56166083259, content=<a href='/topic/show?id=17b8268041b' target=_blank style='color:#2F92EE;'>#使用情况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26804, encryptionId=17b8268041b, topicName=使用情况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=169625169742, createdName=dzx0922897, createdTime=Wed Jun 19 22:52:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1689929, encodeId=da4f1689929d9, content=<a href='/topic/show?id=c5f2226e9d3' target=_blank style='color:#2F92EE;'>#临床使用#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22679, encryptionId=c5f2226e9d3, topicName=临床使用)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=703d28925250, createdName=12498e87m48暂无昵称, createdTime=Wed Jun 26 08:52:00 CST 2019, time=2019-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1258540, encodeId=09521258540d0, content=<a href='/topic/show?id=b0ae365e02f' target=_blank style='color:#2F92EE;'>#卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=18, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36570, encryptionId=b0ae365e02f, topicName=卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cbf451, createdName=陈吴1234, createdTime=Tue Jan 29 02:52:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1291159, encodeId=755712911591b, content=<a href='/topic/show?id=e53140859f6' target=_blank style='color:#2F92EE;'>#国家卫健委#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40859, encryptionId=e53140859f6, topicName=国家卫健委)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba5f232, createdName=zhao4616, createdTime=Tue Jan 29 02:52:00 CST 2019, time=2019-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=359374, encodeId=a7f33593e439, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Sun Jan 27 14:11:01 CST 2019, time=2019-01-27, status=1, ipAttribution=)]
    2019-01-27 医者仁心5538

    学习了

    0

相关资讯

多部委解读药品集中采购:药品降价不降质,解决“带金销售”

1月17日,国务院办公厅印发《国家组织药品集中采购和使用试点方案》(以下简称《方案》),明确了通过招标、议价、谈判等不同形式确定的集中采购品种,试点地区公立医疗机构应优先使用以及保证回款,医保基金应在总额预算的基础上,按不低于采购金额的30%提前预付给医疗机构等内容。自2018年8月,医保局集中采购试点座谈会召开以来,“带量采购”一直牵动着行业的神经。2018年11月14日,中央全面深化改革委

又有药品婴幼儿禁用 中成药说明书规范化道阻且长

又有中成药修改了说明书。1月4日,国家药监局发布了新的中成药说明书修改的公告,本次包括肿节风注射液、小金制剂(小金片、小金丸、小金胶囊等)。对于被修改的2种药物,总结一下,主要是两点:一是增加了药品的禁忌症;二是对不良反应和注意事项等内容的一个完善。一、肿节风注射液肿节风具有清热解毒,消肿散结的功效。注射液用于热毒壅盛所致肺炎、阑尾炎、蜂窝组织炎、菌痢、脓肿。肌内注射。这次,肿节风注射液不仅加上了

国家药监局:这5个药全国禁用!

▍这个药全国禁用日前,国家药监局官网发布消息:全国停止生产、销售、使用吡硫醇注射剂!国家药监局表示,吡硫醇注射剂存在严重不良反应,在我国使用风险大于获益。资料显示,此品种适应症为本品适用于脑外伤后遗症、脑炎及脑膜炎后遗症等。药监局数据中心显示,共有19家药企持有相关批文,包括盐酸吡硫醇氯化钠注射液、盐酸吡硫醇注射液和注射用盐酸吡硫醇。▍4个药,全国不准卖、不准用据统计,在过去的一年,被全国禁用、限

国家药品集中采购北京等11城市试点

国务院办公厅日前印发《国家组织药品集中采购和使用试点方案》(以下简称《方案》),对国家组织药品集中采购和使用试点工作作出部署

药品集中采购试点方案公布:带量采购,量价挂钩、以量换价

1月17日,国务院办公厅印发国家组织药品集中采购和使用试点方案的通知,公布了试点方案全文(以下简称“方案”)。该方案的目标任务是实现药价明显降低,减轻患者药费负担;降低企业交易成本,净化流通环境,改善行业生态;引导医疗机构规范用药,支持公立医院改革;探索完善药品集中采购机制和以市场为主导的药品价格形成机制。目前该方案的试点范围为北京、上海、天津、重庆四个直辖市,以及沈阳、大连、厦门、广州、深圳

药品有效期是否就等于使用期?

药品有效期是指药品在规定的贮存条件下保证药物质量的期限。是根据药品的稳定性不同,通过稳定性实验研究和留样观察而制订的。